Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: October Update

Performance overview
Value at beginning of month: $115,325.33
Value at end of month: $120,535.66
Month over month change: +4.51%
Total CAGR: 25.34%

Related indices, monthly change
NASDAQ: +3.16%
IVV (iShares Core S&P 500): +2.56%
IBB (iShares NASDAQ Biotechnology Index): -5.24%
MXI (iShares Global Materials): +3.24%
VEGI (iShares MSCI Global Agriculture Producers): +2.28%
ICLN (iShares Clean Energy): +3.67%

Individual performances

g4778.png

The index again reached record highs. Its gains came from Genscript and Novozymes, who make up around 50% of the index and both were up modestly in October. Intrexon and Calyxt, the next largest members of the index led losses, which tempered the gains of the index during the month.

Changes made to index

None, you can view the index here.

Allocation as of October 27, 2017

g4165.png

Calvin Schmidt Synthetic Biology Index: November Update

Calvin Schmidt Synthetic Biology Index: September Update